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Background: Childhood apraxia of speech (CAS) is a rare, severe, persistent pediatric motor speech disorder with
associated deficits in sensorimotor, cognitive, language, learning and affective processes. Among other
neurogenetic origins, CAS is the disorder segregating with a mutation in FOXP2 in a widely studied,
multigenerational London family. We report the first whole-exome sequencing (WES) findings from a cohort of 10
unrelated participants, ages 3 to 19 years, with well-characterized CAS.
Methods: As part of a larger study of children and youth with motor speech sound disorders, 32 participants were
classified as positive for CAS on the basis of a behavioral classification marker using auditory-perceptual and
acoustic methods that quantify the competence, precision and stability of a speaker’s speech, prosody and voice.
WES of 10 randomly selected participants was completed using the Illumina Genome Analyzer IIx Sequencing
System. Image analysis, base calling, demultiplexing, read mapping, and variant calling were performed using
Illumina software. Software developed in-house was used for variant annotation, prioritization and interpretation to
identify those variants likely to be deleterious to neurodevelopmental substrates of speech-language development.
Results: Among potentially deleterious variants, clinically reportable findings of interest occurred on a total of five
chromosomes (Chr3, Chr6, Chr7, Chr9 and Chr17), which included six genes either strongly associated with CAS
(FOXP1 and CNTNAP2) or associated with disorders with phenotypes overlapping CAS (ATP13A4, CNTNAP1, KIAA0319
and SETX). A total of 8 (80%) of the 10 participants had clinically reportable variants in one or two of the six genes,
with variants in ATP13A4, KIAA0319 and CNTNAP2 being the most prevalent.
Conclusions: Similar to the results reported in emerging WES studies of other complex neurodevelopmental
disorders, our findings from this first WES study of CAS are interpreted as support for heterogeneous genetic origins
of this pediatric motor speech disorder with multiple genes, pathways and complex interactions. We also submit
that our findings illustrate the potential use of WES for both gene identification and case-by-case clinical
diagnostics in pediatric motor speech disorders.
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Whole-exome sequencingBackground
Next-generation sequencing continues to transform gen-
omic research and clinical practice. Reductions in the time
and cost required to sequence and analyze an individual’s
genome or exome (the exonic subset of the genome) have
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reproduction in any medium, provided the orvariations underlying monogenetic and multigenetic dis-
eases and disorders [1-7]. Interpretation of genetic find-
ings in a clinical setting is scarcely a new challenge, but
the complexity of this task is increased in next-generation
sequencing because of the dramatic increase in dataset
size. In the present study, we sought to determine whether
whole-exome sequencing (WES) of a small number of in-
dividuals could be used to identify variants in candidate or
novel genes that may be causally associated with a rare,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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apraxia of speech (CAS).
Childhood apraxia of speech
CAS, also termed developmental verbal dyspraxia in med-
ical and international contexts, is “a neurological childhood
(pediatric) speech sound disorder in which the precision
and consistency of movements underlying speech are im-
paired in the absence of neuromuscular deficits (e.g., ab-
normal reflexes, abnormal tone)” [8]. As in other apraxias
(for example, limb apraxia and nonverbal oral apraxia),
only volitional (willful, purposeful) movement patterns are
affected. The core speech-processing impairment in CAS
is in transcoding linguistic representations into the plans
for movements that produce articulate speech [9,10]. CAS
can occur congenitally or be acquired anytime during the
period of speech acquisition, nominally from birth to age
nine years. Both onsets of CAS can occur idiopathically, in
the context of a number of complex neurodevelopmental
disorders or in association with a neurological event [11].
The severity of an individual’s apraxia of speech through-
out the lifespan can range from mild to severe, with more
recent reviews indicating that individuals may normalize
speech but not all prosodic features [8,12]. A central ques-
tion is whether neurocognitive and neuromotor processing
deficits in CAS are substantially similar to those described
in adult-onset apraxia of speech, which most frequently is
consequent to stroke [13,14] but also occurs as a primary
progressive disorder [15]. In the following sections, we re-
view the findings reported in the literature for variants and
genes associated with CAS.
Childhood apraxia of speech and FOXP2
The first variant causally associated with CAS was a het-
erozygous missense mutation in the FOXP2 forkhead box
gene segregating with non–word repetition task deficits
and orofacial apraxia in half of the members of a multi-
generational family (“KE”) [16]. FOXP2 codes for a protein
from the FOX family of winged helix/forkhead transcrip-
tion factors. It is expressed widely in the fetal and adult
brain, where it regulates the expression of other genes
within and among cortical, basal ganglia and cerebellar
circuits [17,18]. The expression pattern is specific to de-
fined neuronal subpopulations in these different structures
(for example, deep layers of the cortex, medium spiny
neurons of the striatum and Purkinje cells in the cerebel-
lum). Deficits in these regions during embryogenesis and/
or postnatal development are risk factors for early and
persistent speech-language disorder and associated cogni-
tive, sensorimotor, learning and affective deficits [19,20].
In addition to other reports of participants with FOXP2
disruptions, some to all of whom had suspected CAS
[21-24], several recent reports using contemporary inclu-
sion criteria to identify CAS and other motor speechdisorders have replicated and extended the speech-
language and neurocognitive phenotype associated with
FOXP2. A two-part study series of a mother and daughter
with CAS and a breakpoint in a balanced 7;13 transloca-
tion disrupting FOXP2 reported speech profiles consistent
with both apraxia and dysarthria [20,25]. Recent neuroim-
aging studies of affected KE family members have also
reported speech and neural substrates consistent with
apraxia and dysarthria [26]. A report of a mother and son
with CAS and a submicroscopic deletion of FOXP2 [19]
also described apraxia, dysarthria and cognitive language
profiles similar to those in the KE family and the mother-
and-daughter studies [20,25]. In another report, investiga-
tors described a small de novo intragenic deletion of
FOXP2 presumed to be causal for a severe motor speech
disorder as well as for language and literacy deficits [27].
Behavioral findings in these studies support an emerging
view that, in addition to the signature motor speech deficits
of CAS and dysarthria, FOXP2 disruptions are associated
with deficits in attentional, auditory-perceptual, sensori-
motor, cognitive-linguistic and affective processes [14,28].
In several studies in which suspected CAS and large-scale
deletions that affect FOXP2 were reported, the large num-
ber of genes affected raises the possibility of modifier gene
effects [22,24]. To date, in all cases in which smaller FOXP2
variants were associated with CAS, the variants were found
in a heterozygous state [16,21,29,30].
A widely cited genetic study of 49 speakers (from several
countries) suspected to have CAS identified only one par-
ticipant (and two of his nuclear family members) with a
mutation in FOXP2 [30]. Findings from this study and un-
published estimates of the attributable risk of FOXP2 for
CAS have been interpreted to indicate that the risk is low
(approximately 2%). The constraint on this interpretation is
the high rates worldwide of false-positive diagnoses of CAS,
which are estimated to be as high as 80% in the most com-
prehensive literature reviews currently available [8,12], thus
suggesting the likelihood of a high percentage of false-
positives in the previously referenced clinical sample of
children suspected to have CAS [30]. In a recent report of
24 participants whose suspected CAS was confirmed using
a standardized classification procedure, one participant was
found to have a FOXP2 mutation [29], effectively increasing
this clinical estimate of the attributable risk for CAS of a
FOXP2 mutation or disruption to approximately 4%.
Reviews of the extensive avian and murine Foxp2
modeling literature, as well as the considerable litera-
ture on the role of this gene in evolutionary biology, are
beyond the scope of the present paper. Reviews describe
the array of Foxp2 model findings consistent with ab-
normal vocal development and performance (for ex-
ample, disrupted synaptic plasticity in the striatum,
cerebellar and radial glial cell abnormalities, abnormal
esophageal development and mild to severe motor
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null Foxp2 mice have cerebellar abnormalities with in-
completely folded folia, as well as embryonic, neonatal
or perinatal lethality, whereas the heterozygous muta-
tion does not result in premature death but is associated
with modest developmental delay, abnormal motor
learning and a significant alteration in ultrasonic
vocalization in response to parental separation (for ex-
ample, see [38-40]).Childhood apraxia of speech, CNTNAP2 and FOXP1
A number of additional candidate genes and variants have
been described in the emerging CAS genetics literature and
associated verbal traits and disorders literature. The widely
studied CNTNAP2 gene encodes a member of the neurexin
family, which functions in the vertebrate nervous system as
cell adhesion molecules and receptors [41,42]. CNTNAP2
has been implicated in intellectual disability [43,44], cortical
dysplasia-focal epilepsy syndrome and the related Pitt-
Hopkins-like intellectual disability [43], autism [41,45,46]
and language impairment [47,48]. A recent review de-
scribed CNTNAP2 in the context of neurogenetic networks
during development and summarizes the known informa-
tion on the regulation and function of this gene [49]. Not-
ably, findings implicating CNTNAP2 in both autism [41]
and language impairment without autism [47] suggest dis-
tinct CNTNAP2 pathways for verbal trait disorders, includ-
ing CAS. In one study, investigators posited that variants in
CNTNAP2 and FOXP1 may interact to contribute to the
phenotype of an individual [50]. Several useful reviews of
genetic findings in verbal trait disorders, including CAS, are
available in the literature (for example, see [27,36,51-55]).Childhood apraxia of speech in complex
neurodevelopmental disorders
We have proposed that, especially in view of the low-point
prevalence of idiopathic CAS, estimated at 1 per 1,000 to 1
per 3,000 in 3- to 6-year-old children in the general popula-
tion [8,12], studying CAS in the context of complex
neurodevelopmental disorders provides a rich source of
comparative information on genomic pathways [11]. CAS
has been reported in association with a number of complex
neurodevelopmental disorders, including galactosemia [56],
rolandic epilepsy [57-59], 16p11.2 microdeletions [60,61]
and Williams-Beuren microduplication [62,63]. Prelimin-
ary reports also indicate speech phenotypes consistent
with CAS in participants with Down syndrome [9] and
22q11 microdeletion syndrome [64]. Clearly, in addition
to the singular finding that disruptions in FOXP2 are a
sufficient (monogenic) cause of CAS, continuing research
cited in a later section supports heterogeneous genomic
pathways to CAS.Statement of purpose
The study reported herein had two goals. The first was to
identify, in a sample of well-characterized participants with
idiopathic CAS, candidate genomic variants supporting lit-
erature trends indicating genetic heterogeneity in CAS. The
term well-characterized is important because the most sig-
nificant methodological problem in all studies of speech
impairment consistent with CAS, including those in the lit-
erature on CAS in participants with FOXP2 mutations and
disruptions, is the lack of consensus on the inclusionary cri-
teria to classify participants as positive for CAS. The second
goal was to evaluate the use of next-generation sequencing
in the clinical establishment of disease pathogenicity in this
and other pediatric motor speech disorders. Both goals are
motivated by reports in other contexts of the significant
clinical potential of sequencing for an eventual understand-




Ten participants with the clinical diagnosis of CAS or
suspected CAS were enrolled for a study of pediatric
motor speech sound disorders. They were recruited and
consented using procedures approved by institutional re-
view boards at two collaborative sites. A trained exam-
iner at each site administered the Madison Speech
Assessment Protocol (MSAP), a lifespan assessment
protocol for diagnostic classification of pediatric speech
sound disorders, including CAS [70,71]. A total of 15
speech tasks provide age-sex standardized scores on the
competence, precision and stability of a speaker’s speech,
prosody and voice. Audiorecordings of the speech sam-
ples obtained from all MSAP tasks were processed using
computer-aided methods for perceptual and acoustic
analyses. Each of the 10 participants met classification
criteria for CAS based on their standardized scores on a
diagnostic marker of CAS and supplementary documen-
tation with high to conclusive diagnostic accuracy [9].
Table 1 gives the phenotype information for the 10 par-
ticipants. All participants were self-reported as white; no
additional heritage information was collected. Individual
phenotype information was obtained from the parent
questionnaire, and direct assessment measures are cited in
the Table 1 footnotes. To maintain participant anonymity,
individual participant data are aggregated in three devel-
opmental age groups.
The 10 participants were evenly divided by gender, a
sampling outcome not representative of the 70% and
higher prevalence of males typically reported in studies of
idiopathic CAS [8,12]. Participants include three preschool
children ages 3 to 6 years (age group A), three early
school–age children ages 7 to 9 years (age group B) and
four older participants ages 10 to 19 years (age group C).















Onsete Comprehensionf Expressionf Grossg Oral
nonverbalh
1 M C 7+ + + + + + + +
2 M A 3 + + + + ND
3 F C 6 ND + + + ND ND
4 M C 6 + + + +
5 F C 7+ + + + + + + ND
6 F A 5 + + + + +
7 F B 4 + ND + +
8 M B 3 + + ND ND + +
9 F A 4 + + + +
10 M B 5 + + + + + +
aPlus signs indicate impairment. Blank cells indicate negative history or performance within normal limits. ND indicates no available data. bAge groups: A = 3 to 6
years; B = 7 to 9 years; C = 10 to 19 years. cOne or more nuclear family members with a verbal trait disorder, including speech disorder, language disorder,
reading disorder, cognitive disability or learning disability. dComposite IQ <85 [72]. eLate onset of babbling, first word, two words together or short phrases per
parent report, fListening Comprehension and Oral Expression Scales standard scores <85 [73]. gParent report or history of physical or occupational therapy. hOral
nonverbal motor assessment tasks.
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pants documents the persistence of CAS. For many to
most individuals with CAS, residual speech-language defi-
cits persist over the lifespan, frequently including residual
speech errors, inappropriate pausing, inappropriate lin-
guistic stress and slow speech rate [9].
Familial aggregation was considered to be positive if
one or more of the participant’s nuclear family members
had a history of any type of speech sound disorder, ad-
justed for missing data. The 56% familial aggregation
rate in Table 1 is consistent with familial aggregation es-
timates for convenience samples of children with the
most common form of speech sound disorder, termed
speech delay [74], supporting the likelihood that at least
some forms of both idiopathic speech delay and idio-
pathic CAS are inherited. The design of the present
study did not allow for follow-up segregation analyses.
Although a history of other forms of speech disorders
was present in family members, the case history infor-
mation indicated that none of the 10 participants had a
nuclear family member with a clinical diagnosis of CAS.
The profiles of cognitive, language and motor impair-
ment characteristics of the 10 participants with CAS were
similar to those summarized in the two most recent com-
prehensive reviews of CAS research [8,12]. Profiles were
also similar to behavioral data in these domains for af-
fected family members in three published reports of fam-
ilies with FOXP2 mutations [19]. Adjusted for missing
data, 30% of this sample of 10 participants with idiopathic
CAS met assessment criteria for cognitive disability, 100%
were delayed in the onset of speech and language, and
78% had active, persistent impairments in either or both
language comprehension and language expression. Last,89% and 100% of participants, respectively, had some level
of impairment in gross motor and oral nonverbal move-
ments. As discussed elsewhere and cited previously, these
behavioral profiles of CAS are consistent with emerging
perspectives on CAS as a multiple-domain disorder in-
volving deficits in auditory-perceptual encoding and mem-
ory processes in addition to the signature motor speech
deficit [14].
FOXP2 sequencing
All 10 participants were evaluated for FOXP2 mutation
status by sequencing each of the seventeen FOXP2 coding
exons [NCBI:NM_014491.3]. The exons were amplified by
polymerase chain reaction (PCR) (AmpliTaq Gold PCR
Master Mix; Applied Biosystems, Carlsbad, CA, USA)
using oligos referenced elsewhere [29]. PCR amplification
and amplicon size were verified by gel electrophoresis. Se-
quences of each PCR amplicon were generated in both
forward and reverse direction sequencing reactions using
the BigDye Terminator v3.1 Cycle Sequencing Kit (Ap-
plied Biosystems), purified with AxyPrep Mag DyeClean
beads (Axygen Biosciences, Union City, CA, USA) and
run using either an ABI 3730xl or 3130xl DNA Analyzer
(Applied Biosystems). No FOXP2 variants of note were
identified.
Whole-exome sequencing: primary and secondary
analysis
We completed WES for each participant by subjecting
whole-blood–derived genomic DNA to in-solution hy-
brid capture and Illumina sequencing. Library prepar-
ation, sequencing, read mapping and variant calling were
performed at the University of Wisconsin Biotechnology
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DNA Sample Prep Kit (Illumina, Inc, San Diego, CA,
USA) with the following modification to the manufac-
turer’s protocol: DNA was sheared using the Bioruptor
XL (Diagenode sa, Liege, Belgium) for 30 minutes using
a cycle of 30 seconds on followed by 30 seconds off on
high power. After adapter ligation, samples were size-
selected to an average size of 300 ± 50 bp using an
Invitrogen E-Gel SizeSelect 2% Agarose Gel (Life Tech-
nologies, Grand Island, NY, USA). Solution hybrid cap-
ture was performed on the completed libraries using the
Agilent SureSelect Human All Exon Capture System
(Agilent Technologies, Santa Clara, CA, USA), either 38
Mb (participants 3, 5, 6, 7 and 8) or 50 Mb (participants
1, 2, 4, 9 and 10) with minimal modification of the man-
ufacturer’s protocol.
The finished libraries were quantified using PicoGreen
fluorometric dye (Life Technologies), and quality was
assessed using the Agilent Bioanalyzer with DNA 1000 Kit
chips (Agilent Technologies). Completed libraries were
sequenced using the Illumina Genome Analyzer IIx Se-
quencing System (paired-end 75-bp reads). Sequencing
produced between 23 million and 45 million passing filter
reads per library. Reads were mapped to the human refer-
ence genome assembly, and variant calling (for substitu-
tions, insertions and deletions) was performed using
Illumina Consensus Assessment of Sequence and Vari-
ation (CASAVA) software. Because of the noted lack of
maturity of the available exome-based structural variant
calling algorithms [75], we did not undertake calling of
this class of variants. Table 2 provides information on the
sequencing runs and output. Although there is variation,
exome sequencing for all samples was carried out to suffi-
cient depth to differentiate sequencing or mapping errors
from heterozygous or homozygous variants. An average of
116,836 high-quality variants were called per sample.
Tertiary analysis
Tertiary analysis aimed at identifying candidate disease-
causing variants was performed using CarpeNovo, a tertiary
sequencing analysis software platform developed to support
the Genomic Medicine Clinic and Program at Medical
College of Wisconsin/Children’s Hospital of Wisconsin
(MCW/CHW). This Java- and Oracle-based platform has
been used at MCW/CHW to identify causative mutations
in a variety of disorders (for example, see [67,69]) and has
undergone the rigorous testing and validation required for
use in this clinical setting. Upward of 100 annotations were
tagged to each of the WES-identified variants. CarpeNovo
was subsequently used to prioritize some and deprioritize
other variants to produce a targeted subset of compelling
variants within known or novel candidate genes. Specific-
ally, we prioritized the variants guided by the six assump-
tions outlined in the paragraphs below.First, because CAS is a rare disorder and mutations
reported to be associated with the phenotype or overlap-
ping phenotypes (for example, autism) have also been
novel or rare, we expected the candidate variants to have
a low allele frequency within control populations. We
therefore deprioritized found variants that have an allele
frequency greater than 0.3% in the Single-Nucleotide
Polymorphism Database, build 137; the National Heart,
Lung, and Blood Institute Exome Sequencing Project
6500 dataset obtained via the Exome Variant Server ftp
site; the 1000 Genomes Project variant dataset available
from their download site; or our in-house–derived
dataset of 128 exomes or genomes.
Second, we prioritized variants based on their likelihood
of being deleterious to the normal functioning of the gen-
omic feature, following the American College of Medical
Genetics and Genomics (ACMG) guidelines on classifica-
tion of variants (outlined in Table 3). Specifically, variants
were prioritized into three classes: (1) variants already
shown to impact function of the underlying genomic fea-
ture (for example, transcript, binding site and promoter);
(2) variants of a type likely to impact the function of the
underlying feature, that is, premature stop causing, start
codon altering, canonical splice site altering, read-throughs
of the stop codon and frame shift causing insertions or de-
letions; and (3) variants of a type that may or may not alter
the function of the feature, that is, near–splice site variants
(within 10 bases of splice sites), in-frame insertions and de-
letions within protein-coding regions and protein-coding
nonsynonymous (NS) changes that were predicted to be
damaging by algorithms designed to predict the effect of
such changes, that is, PROVEAN (Protein Variation Effect
Analyzer), SIFT (Scale Invariant Feature Transform), Mu-
tation Assessor, Condel and PolyPhen-2. The remaining
variants either could not be prioritized on impact owing to
insufficient data or would not be prioritized because they
were unlikely to cause an effect. Variants that, upon further
analysis, were shown to be undeniably associated with a
phenotype with no conceivable overlap with CAS (based
on expert interpretation) were also excluded from further
consideration.
Third, to exclude sequencing or mapping errors, we
deprioritized variants present in fewer than 10% of reads
at that position.
Fourth, we considered variants supporting an autosomal-
recessive mode of inheritance and variants exerting their
effects in a dominant fashion. Although we did not
place a specific filter on zygosity, we did hypothesize
that (1) a variant giving rise to a single defective allele
may well be sufficient to alter speech and language de-
velopment while leaving other gene functions intact
[23,32,35], and (2) a homozygous variant or compound
heterozygote would lead to a more severe or different
phenotype.
Table 2 Sequencing run statistics
Participants Exon capture No. of lanes No. of total reads passing filter Average coverage (80% on target)
1 50 Mb 1 39,188,279 94X
2 50 Mb 1 40,950,124 98X
3 38 Mb 1 15,076,800 48X
4 50 Mb 1 45,037,091 108X
5 38 Mb 2 24,806,520 78X
6 38 Mb 2 20,198,040 64X
7 38 Mb 1 26,815,926 84X
8 38 Mb 2 35,035,920 110X
9 50 Mb 1 42,500,956 102X
10 50 Mb 1 23,439,839 56X
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FOXP2 and CNTNAP2, we postulated that we might not
be looking for a single gene, but rather for variants in
multiple genes giving rise to speech production defects
within neurologic networks. All variants within known
CAS genes were reviewed, as were variants in genes that
had been identified as genes of interest in another sam-
ple. Attempts to require that the candidate variants or
genes be shared across all or the majority of samples
were not fruitful.
Sixth, we excluded variants previously confirmed, in-
house or externally, to be neutral polymorphisms.
Following prioritization, 401 variants on average per
sample remained under consideration (about 0.34%). In
some cases, variants that did not meet these criteria
were reviewed, including those within known CAS genesTable 3 Summary data on variants by classification statusa
Average gene
Highly likely deleterious and rare (<0.03) 49.40
Rare (<0.03) and premature stop 17.40
Rare (<0.03) and read-through 0.25
Rare (<0.03) and start codon changing 0.00
Rare (<0.03) and splice site 6.40
Rare (<0.03) and frame shift insertion 15.40
Rare (<0.03) and frame shift deletion 11.80
Possibly deleterious and rare (<0.03) 207.00
Damaging HumVar PolyPhen NS change 114.60
Damaging SIFT NS change 96.00
Protein coding in-frame insertion 2.00
Protein coding in-frame deletion 4.20
Intronic near-splice 86.20
Any clinical association and rare (≤0.03) 11.80
Prioritized clinically associated with CAS but not rare 0.40
Prioritized clinically associated with CAS and rare (<0.03) 0.40
aCAS, childhood apraxia of speech; NS, nonsynonymous; SIFT, Scale Invariant Featuror genes associated with a phenotype with a potential gen-
etic overlap with CAS (including dyslexia and other types
of speech impairment) or in genes that had been identified
as being of interest in another sample. Each variant
was considered based on variant-specific and feature-level
functional data. A variety of automated data sources (the
Human Genome Mutation Database and the Online Men-
delian Inheritance in Man database) and manually accessed
data sources (Ingenuity Systems IPA pathway analysis
tool (Ingenuity Systems, Redwood City, CA, USA), the
GeneCards compendium (http://www.genecards.org/), the
Rat Genome Database (http://rgd.mcw.edu/), the Mouse
Genome Informatics database (http://www.informatics.jax.
org/) and PubMed (http://www.ncbi.nlm.nih.gov/pubmed/))
were used to examine the function for each candidate. Path-
way analyses were also performed to determine whether anycount Gene range Average variant count Variant range
(44 to 54) 59.20 (53 to 66)
(16 to 27) 21.80 (19 to 27)
(0 to 1) 0.40 (0 to 1)
(0 to 1) 0.60 (0 to 1)
(3 to 8) 6.40 (3 to 8)
(12 to 20) 17.60 (13 to 22)
(6 to 17) 12.00 (6 to 17)
(181 to 219) 239.80 (238 to 249)
(105 to 127) 137.20 (120 to 152)
(78 to 111) 130.40 (111 to 153)
(0 to 6) 2.00 (0 to 6)
(0 to 6) 4.20 (0 to 6)
(76 to 84) 91.80 (78 to 101)
(1 to 16) 12.60 (1 to 14)
(0 to 1) 0.40 (0 to 1)
(0 to 1) 0.40 (0 to 1)
e Transform.
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order. For each variant, the variant impact and the func-
tional association were analyzed in unison to identify
pairings resulting in reportable findings (that is, where there
was a likely impact and the function was already or could be
associated with CAS). The process was performed for each
of the 10 samples to identify variants potentially associated
with altered neural substrates for verbal traits.
Sanger validation
All candidate variants that met evidence thresholds for
clinical reporting were validated. When available, we used
resequencing amplicons (RSA) primers that have been
previously designed to cover coding regions in a selection
of genes. For regions that did not have RSA primers avail-
able, we designed primers using PrimerQuest Software
(Integrated DNA Technologies, Coralville, IA, USA). We
performed PCR using 10 ng of DNA and performed
Sanger capillary sequencing of the PCR product using for-
ward and reverse primers on an ABI 3130xl Genetic
Analyzer.
Results and discussion
For 8 (80%) of the 10 participants, the methods above
identified likely pathogenic variants or variants of uncer-
tain significance (VUS) in genes that have previously
been shown to be causally associated with CAS or
closely related phenotypes. In other participants, we
identified likely pathogenic variants in genes of uncer-
tain significance (GUS). To be clear, we used an annota-
tion of VUS in the same way that it is used in a
diagnostic laboratory according to the ACMG guide-
lines. This definition indicates that we believe the vari-
ants to be excellent candidates for causation of CAS in
these participants. VUS and GUS findings will require
follow-up studies to determine whether associations
reach levels required for clinical support, either through
development of functional assays or by confirmation of
the association through identification of causative vari-
ants in additional unrelated individuals with CAS. In
two participants, we did not identify any reportable find-
ings. Table 4 and Table 5 provide a summary of these
highest-priority variants identified in each of the partici-
pants for each of the 10 participants. With regard to the
two goals of this study, we report not only the patho-
genic/likely pathogenic variants but also the VUS and
GUS findings that could be pathogenic with external
confirmation. The following discussion is ordered by
findings for six genes.
FOXP1
Participant 8 has a heterozygous novel variant yielding a
NS amino acid change in FOXP1 (p.Ile107Thr) predicted
to be damaging by PROVEAN, SIFT, Mutation Assessor,Condel and PolyPhen-2. Isoleucine at this position in
the amino acid sequence is absolutely conserved down
to fish and lies in a highly conserved region of the
protein.
FOXP1 is expressed in particular neuronal subpopula-
tions in the developing brain [76-78], but its precise
roles in brain development have yet to be defined. In
animal models, homozygous loss of FOXP1 causes em-
bryonic, neonatal or perinatal lethality with abnormal
cardiovascular system development, including outflow
tract septation, ventricular septal defects, abnormal car-
diac valve morphology, decreased and irregular heart
rate, disorganized myocardium, thin ventricular compact
zone and edema [79]. In other studies, homozygous
FOXP1 knockouts have shown alterations in develop-
ment of motor neurons in the spinal cord [76,80,81]. In
contrast, mice with heterozygous FOXP1 disruption de-
velop normally with regard to their cardiovascular sys-
tem [79].
FOXP1 is known to have a global impact on neural de-
velopment and has been associated with CAS in a num-
ber of reports [82]. Another study [83] reported two de
novo heterozygous mutations (one small deletion and
R525X) in the FOXP1 gene in two unrelated children
with moderate intellectual disability, expressive language
deficits and autistic features. WES was recently used to
identify variants in FOXP1 causing a frame shift and pre-
mature stop codon in an individual with intellectual dis-
ability, severe autism spectrum disorder and delayed
language [50].
In another study, a heterozygous 785-kb deletion in
3p14.1 that affected FOXP1, EIF4E3, PROK2 and GPR27
was identified in a participant with speech delay, con-
tractures, hypertonia and blepharophimosis [59]. The ef-
fect was attributed to FOXP1, but the effects of PROK2
and GPR27 are unclear, particularly given their known
role in developmental delay [59]. Additional support for
the effects of FOXP1 in this case is provided by a study
that identified a 1-Mb interstitial 3p14.1 microdeletion
including the entire coding region of FOXP1 in an adult
with a recognizable phenotype of autism, motor inco-
ordination, dysmorphic features and severe speech delay
[84]. Another study provided additional evidence of in-
volvement due to a deletion exclusively affecting the
FOXP1 gene in a child with motor development delay
and impaired language acquisition [57]. It was noted that
the presence of a Chiari malformation type I (cerebellar
tonsil abnormality) in this individual could also have
caused or contributed to motor and speech development
delay. Large de novo heterozygous deletions affecting
FOXP1 and other genes were also found in three individ-
uals with moderate intellectual disability, gross motor
delay and severe speech and language impairment char-
acterized by delayed onset of speech, dysgrammatism
Table 4 Summary of most highly prioritized variants in each study participanta
Participants Genes Chromosomes Coordinates EVS allele frequency TGP allele frequency dbSNP ID Zygosity Reads supporting call (%)
1 ATP13A4 Chr3 193,171,979-193,171,979 0.0886 0.05576 rs35424709 Heterozygous 60.47
KIAA0319 Chr6 24,588,884-24,588,884 0.427 0.234 rs4504469 Heterozygous 52.08
2 ATP13A4 Chr3 193,171,979-193,171,979 0.0886 0.05576 rs35424709 Heterozygous 45.76
3 No reportable findings
4 CNTNAP2 Chr7 148,106,475 to 148,106,477 Not found Not found Not found Heterozygous 74.36
ATP13A4 Chr3 193,171,979-193,171,979 0.0886 0.05576 rs35424709 Heterozygous 53.97
5 No reportable findings
6 CNTNAP2 Chr7 146,372,040-146,372,040 Not found Not found Not found Heterozygous 38.46
7 CNTNAP1 Chr17 38,101,263-38,101,263 Not found Not found Not found Heterozygous 40
8 FOXP1 Chr3 71,185,577-71,185,577 Not found Not found Not found Heterozygous 93.33
9 KIAA0319 Chr6 24,588,884-24,588,884 0.427 0.234 rs4504469 Heterozygous 41.96
SETX Chr9 135,204,010-135,204,010 0.0009 0.0096 Not found Heterozygous 48.17
10 CNTNAP2 Chr7 148,106,475 to 148,106,477 Not found Not found Not found Heterozygous 74.36
KIAA0319 Chr6 24,588,884-24,588,884 0.427 0.234 rs4504469 Heterozygous 57.5
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1 ATP13A4 43 NS damaging g.1938A>T p.Glu646Asp ASD, CAS Postulated roles in the developing
nervous system and early
neuronal development
VUS




2 ATP13A4 59 NS damaging g.1938A>T p.Glu646Asp ASD, CAS Postulated roles in the developing





4 CNTNAP2 39 Splice consensus c.3714-7insTTG N/A Intellectual delay, ASD, CAS Local differentiation of axons
into distinct functional subdomains
VUS
ATP13A4 63 NS damaging g.1938A>T p.Glu646Asp ASD, CAS Postulated roles in the developing





6 CNTNAP2 52 NS damaging c.511C>T p.Arg171Cys Intellectual delay, ASD, CAS Local differentiation of




7 CNTNAP1 10 NS damaging c.3191G>A p.Arg1064Gln No human phenotype Formation and maintenance
of neuronal cell connections
VUS in GUS
8 FOXP1 15 NS damaging c.320T>C p.Ile107Thr Developmental delay, expressive language
deficits, ASD




9 KIAA0319 112 NS damaging c.931G>A p.Ala311Thr Developmental dyslexia, SLI Adhesion between migrating
neurons and radial glial fibers
VUS
SETX 191 NS damaging g.2975A>G p.Lys992Arg AOA2 Suggested to be involved
with DNA and RNA processing
VUS in GUS
10 CNTNAP2 39 Splice consensus c.3714-7insTTG N/A Intellectual delay, ASD, CAS Local differentiation of
axons into distinct functional
subdomains
VUS
KIAA0319 80 NS Damaging c.931G>A p.Ala311Thr Developmental dyslexia, SLI Adhesion between migrating
neurons and radial glial fibers
VUS
aAOA2, Ataxia and oculomotor apraxia type 2; ASD, Autism spectrum disorder; CAS, Childhood apraxia of speech; GUS, genes of uncertain significance; NS, nonsynonymous; SLI, specific language impairment; VUS,
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http://www.jneurodevdisorders.com/content/5/1/29and poor speech articulation [58]. A de novo intragenic
FOXP1 deletion was also seen in an individual with both
intellectual disability and severe language impairment,
particularly regarding expressive language [83].
Together, the findings from these studies provide com-
pelling evidence that disruptions in the FOXP1 gene can
be causative of multiple neurodevelopmental abnormal-
ities, including specific language impairment (SLI). Thus,
although the variant in the present paper has not previ-
ously been reported, it is of a type that would be expected
to alter function and was found in a gene shown to be
causally associated with the same or a related clinical
phenotype. The participant has only a single heterozygous
variant, but that has been shown to be sufficient for dis-
ease. This individual has the cognitive impairments and
gross and oral nonverbal motor impairment seen in many
other individuals with FOXP1-associated CAS (Table 1).
This variant reaches required levels of evidence and is
reported as a likely pathogenic variant.
CNTNAP2
Participant 6 was found to have a heterozygous novel vari-
ant giving rise to a NS amino acid change in the
CNTNAP2 gene (p.arg171Cys) predicted to be damaging
(by PROVEAN, SIFT, Condel, Mutation Assessor and
PolyPhen-2). The variant has not previously been reported
but is of a type that would be predicted to alter appropri-
ate functioning of the gene.
The CNTNAP2 gene is widely studied in verbal trait
disorders [41,42]. It is expressed at high levels in the
prefrontal and anterior temporal cortex, as well as in the
dorsal thalamus, caudate, putamen and amygdala [85].
The protein is localized at the juxtaparanodes of myelin-
ated axons, is associated with potassium channels and
has been postulated to play a role in the local differenti-
ation of the axon into distinct functional subdomains.
Homozygous mouse models of CNTNAP2 show abnor-
malities in the central nervous system, leading to abnor-
mal neuronal migration, corpus callosum structure and
interneuron morphology, in addition to abnormal spatial
learning, abnormal coordination and interaction behav-
ior, including abnormal vocalization.
CNTNAP2 has been associated with intellectual disability
[43,44]; language delays in children with autism [45]; the
language deficits and repetitive, stereotyped behavior in
autism [41,46]; and SLI without autism spectrum disorder
[47,48]. Large-scale genotyping studies of CNTNAP2 have
been completed with participants who have deficits in
common forms of SLI [47] and with delays in the age of
the first spoken word in participants with autism [48]. De-
letions of this gene have been associated with speech and
mild motor delay in a single male participant, although this
was complicated by a milder phenotype in a sibling sharing
the same deletion [86]. Another speech study identifieddeletions in this gene in one child with CAS [29]. The
identified deletion maps within the noncoding portion of
the gene (intron 13) but may affect regulatory elements im-
portant for appropriate expression. Given the reports
supporting causative associations between CNTNAP2 and
CAS, this variant reaches required levels of evidence for
clinical reporting as a likely pathogenic variant in CAS.
Participants 4 and 10 both share a novel, interesting
variant in CNTNAP2: a heterozygous insertion of three
nucleotides directly neighboring the splice site (within
the splice consensus sequence at position −7). Heterozy-
gous splice site variants in this gene have previously
been associated with autism spectrum disorders and de-
velopmental language impairment [43]. Those investiga-
tors suggested that a milder phenotype is associated
with heterozygous variants, whereas homozygous or
compound heterozygous defects are associated with se-
vere intellectual disability, including cortical dysplasia-
focal epilepsy syndrome and the related Pitt-Hopkins-like
mental retardation. Because of insufficient evidence on the
deleterious nature of this variant, the near-splice insertion
in participants 4 and 10 is reported as a VUS in a gene
strongly associated with CAS.CNTNAP1
Participant 7 has a novel heterozygous variant giving rise to
a NS amino acid change in CNTNAP1 (p.Arg1064Gln,
c.3191G>A) predicted to be damaging (by PROVEAN,
SIFT, Condel, Mutation Assessor and PolyPhen-2). The
variant has not previously been reported but is of a type
that may alter function.
CNTNAP1 protein is transcribed predominantly in brain
tissue and associates with the contactin-PTPRZ1 complex,
which is known to play a critical role in the formation and
maintenance of neuronal cell connections [87-89]. The
CNTNAP1 extracellular domain architecture has been pos-
tulated to be the signaling subunit of contactin, enabling re-
cruitment and activation of intracellular signaling pathways
in neurons. Neurodegenerative phenotypes, including im-
paired balance, paresis, hypoactivity and ataxia and embry-
onic, neonatal or perinatal lethality are seen in homozygous
CNTNAP1 mouse models [90,91]. Abnormal axon morph-
ology, hypermyelination and nerve conduction are present.
A milder, nonlethal phenotype (albeit with ataxia and abnor-
mal motor coordination), without the serious morphological
alterations seen in homozygotes, is seen in heterozygous
mice.
We hypothesize that this heterozygous variant in
CNTNAP1 may be deleterious in participant 7, but this
finding does not reach required levels of evidence for clin-
ical reporting. For CAS, we consider CNTNAP1 a GUS.
Confirmation of the role of CNTNAP1 in CAS will require
additional studies of the type illustrated in this report.
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Participant 9 has a novel heterozygous variant giving rise
to a NS amino acid change in SETX (p.Lys992Arg,
g.2975A>G) predicted to be damaging (by PROVEAN,
SIFT, Condel, Mutation Assessor, and PolyPhen-2). The
variant has previously been reported in cis with H2197R in
a participant with ataxia and oculomotor apraxia type 2
(AOA2). AOA2 is a neurodegenerative disorder character-
ized by elevated levels of serum α-fetoprotein, cerebellar at-
rophy, gait ataxia, peripheral sensorimotor neuropathy,
areflexia, saccadic ocular pursuit with nystagmus and vari-
able oculomotor apraxia. Onset ranges from childhood
through early adulthood, with the majority of cases arising
during adolescence. Senataxin protein is produced in a
wide range of tissues, including the brain, spinal cord and
muscles. This variant is found in the DNA/RNA helicase
domain of the protein. Dysarthria has been seen in all pub-
lished cases of AOA2, including in participants with the
previously reported p.Lys992Arg variant [92]. Both exonic/
multiexonic deletions and duplications that disrupt SETX
leading to AOA2 have been reported [93-95]. AOA2 is
inherited in an autosomal-recessive manner [93,94]. This
variant is reported as a VUS in a gene previously associated
with an overlapping phenotype.KIAA0319
Participant 1 has a variant of interest in the KIAA0319
gene. The variant (p.Ala311Thr, c.931G>A) is believed
to be damaging, having been associated with dyslexia
and SLI in multiple unrelated families [96,97]. This vari-
ant was deprioritized in the first analytic focusing on
rare alleles due to an allele frequency that was higher
than the allele frequency threshold applied. The variant
was, however, noted to be of interest in our analysis of
predicted deleterious variants previously associated with
potentially associated phenotype, where we place less
weight on the currently predicted allele frequency.
KIAA0319 has a role in appropriate adhesion between
migrating neurons and radial glial fibers and may also regu-
late growth and differentiation of dendrites in the develop-
ing brain [97-99]. The gene has four polycystic kidney
disease domains with homology to the extracellular do-
mains of the PKD protein PKD1, which are involved in
cell-adhesive functions [100]. Both tissue-specific and tem-
poral expression patterns in the frontal and cerebral neo-
cortex, ganglionic eminence, mesencephalon, hippocampus
and dentate gyrus and in the Purkinje cell layer of the cere-
bellum correspond well with the known process, timing
and localization of neuronal migration [97]. RNA interfer-
ence (RNAi) of KIAA0319 in rats was shown to disrupt
neuronal migration and taken as evidence of a role for
KIAA0319 in neuronal migration during formation of the
cerebral cortex [101].Using linkage and association analyses, KIAA0319 has
been shown to have a strong association with language
impairment phenotypes, including articulation, text read-
ing and general language skills [97,102,103]. In one study,
investigators found strong associations of three single-
nucleotide variants (SNVs) with altered speech, language
and reading phenotypes, including one of the variants (p.
Ala311Thr) found in participant 1 [104]. This finding was
later supported in two studies [102,105]. The overlap be-
tween an SLI phenotype and dyslexia is particularly inter-
esting, given the extensive comorbidity (40% to 55%)
reported for these two disorders [106]. The p.Ala311Thr,
c.931G>A variant previously associated with SLI was also
found to be a heterozygous deleterious variant in partici-
pants 9 and 10. This variant in these participants can
therefore be reported as a VUS in CAS due to consider-
ation of the allele frequency and functional and pheno-
typic data. On the basis of the comparison of the amino
acid length, number of known polymorphisms and num-
ber of NS variants predicted to be damaging, this gene ap-
pears to be relatively highly conserved, in line with other
known causal genes. A number of other KIAA0319 vari-
ants were seen in the present participants, but all were
deemed to be benign. None remained under consideration
after application of the six prioritization guidelines.ATP13A4
Participant 1 has a heterozygous, relatively rare (esti-
mated frequencies between 0.056 and 0.088, depending
on the database queried), highly conserved variant
(rs35424709) that gives rise to a NS amino acid change
in ATP13A4 (g.1938A>T, p.Glu646Asp). Despite this
somewhat higher frequency, this variant was prioritized
for consideration because this gene was previously caus-
ally associated with an overlapping phenotype.
ATP13A4 is the least studied member of the subfamily
of P5-type ATPases but has recently been postulated to
play a vital role in the developing nervous system in
early neuronal development [107]. The variant is located
close to the conserved phosphorylation site (D468) and
the nucleotide-binding domain of the protein. ATP13A4
is highly expressed in areas of the brain known to be re-
sponsible for language, including the lateral inferior
frontal cortex (Broca’s area) and the temporoparietal cor-
tex (Wernicke’s area) [108]. Based on comparison of the
amino acid length, number of known polymorphisms
and number of NS variants predicted to be damaging,
this gene appears to be relatively highly conserved, in
line with other known causal genes. Although some
damage prediction tools predict this change to be dele-
terious (Mutation Assessor, Condel, PolyPhen-2), others
predict a neutral effect (PROVEAN, PolyPhen-2). An
existing study of six individuals with autism spectrum
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phenotypic information is provided for the six study par-
ticipants, so it is not possible to determine whether they
have SLI or CAS phenotypes that could be associated
with this variant in addition to their autism spectrum
classification. Although language impairment is a major
component of autism, individuals with autism may have
a subtype of language disorder that differs from the type
associated with CAS [109]. Thus, this study provides
some support for a deleterious annotation for this vari-
ant, but the lack of participant phenotype information
precludes speculation on causal pathways.
Notably, ATP13A4 has previously been causally associ-
ated with CAS. A paracentric inversion disrupting the gene
was identified in a seven-year-old girl with clinically de-
fined expressive and receptive language delay [108]. The
same inversion was found in the girl’s father, who also had
language impairment. Expression analysis showed that the
inversion resulted in inactivation of one copy of ATP13A4
in each individual. Furthermore, one study recently pro-
vided functional evidence of the deleterious impact of the
Glu646Asp variant in a mouse model [107]. Expression
analysis of the wild-type and Glu628Asp (Glu646Asp
orthologous equivalent) protein variant showed that the
variant has no intrinsic calcium pump activity. The variant
was shown to impair ATP13A4 regulation of calcium trans-
port to a significantly higher degree than that seen in alter-
ation of the known phosphorylation site (D468Val) [107].
The ATP13A4 variant was also found in two other partic-
ipants in the present study: participants 2 and 4 (Table 4).
Thus, three participants with CAS have the same variant,
each in a heterozygous state. The existing functional evi-
dence for a deleterious impact and the existing CAS associ-
ations in three unrelated participants with the same
variants is interpreted as providing strong support for a
causative role of the ATP13A4 variant in CAS. The allele
frequency is higher than expected, however, based on the
rarity of this condition. Because of the latter and despite all
of the functional and case study evidence in existence, we
report this ATP13A4 variant as a VUS in the present study
for CAS in these three participants.
Conclusions
The two goals of the present study were (1) to identify
genomic variants in participants with CAS supporting
literature trends indicating genetic heterogeneity and (2)
to evaluate the productivity of WES for genomic studies
in this and other pediatric motor speech disorders.
Regarding the first study goal, our findings support
likely causal pathogenic mutations in two participants
and additional clinically reportable variants in six of the
remaining eight participants. A total of three partici-
pants had prioritized variants in two of six widely stud-
ied genes on five chromosomes. Participant 1 had notedvariants in both ATP13A4 and KIAA0319. Participant 4
had noted variants in ATP13A4 and CNTNAP2. Partici-
pant 10 had noted variants in KIAA0319 and CNTNAP2.
In each of the three participants, the two genes reviewed
are expressed in early neuronal development. These
findings are consistent with the possibility of a two-hit
causal mechanism, with interaction between genes or as-
sociation within tightly regulated networks underlying
participants’ behavioral phenotypes. Multiple-hit mecha-
nisms have been posited in studies of autism and other
neurodevelopmental syndromes [110,111].
With regard to the second study goal, the establishment
of disease pathogenicity using next-generation sequencing
remains controversial. For more than a decade, the pre-
vailing perspective has been that implicating a causal gene
or variant requires statistical confidence that there is less
than a 1 in 1 million probability of finding the association
by chance [112]. Without the availability of genome data
from family members, we understood that our study
would not be adequately powered to document new CAS
genes. Rather, the second study goal was to evaluate the
potential productivity of next-generation sequencing in
CAS and other pediatric motor speech disorders.
We conclude that our findings demonstrate the potential
productivity of next-generation sequencing in larger-scale
genetic studies of simplex cases of CAS and possibly other
motor speech disorders. In the present study, in which we
used WES, we found a 60% success rate in detecting likely
causal gene variants in the 10 present participants, com-
pared to recent anecdotal estimates of 25% to 30% success
rates in WES studies of other complex neurodevelopmental
disorders. Crucially, the difference may reflect the strict in-
clusionary criteria for the disorder targeted in this study.
Given that clinical exome sequencing currently costs less
than $5,000 per patient, the cost of Sanger sequencing of
all six target genes is now significantly in excess of whole-
exome sequencing. Furthermore, the current list price for
single-gene testing for FOXP2 is over $2,250. In this situ-
ation, the cost per diagnosis made is significantly lower if
whole-exome sequencing is performed ($8,333 per diagno-
sis assuming a 60% diagnosis rate and $16,666 assuming a
30% diagnosis rate) rather than single-gene testing on
FOXP2 ($56,250 per diagnosis assuming a 4% diagnosis
rate). For well-phenotyped participants, next-generation se-
quencing of pediatric motor speech disorders likely may be
a cost- and time-effective method of choice for both disease
gene variant discovery and for clinical applications.
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